Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson's disease

Siddharth Arora; Naomi P. Visanji; Tiago A. Mestre; Athanasios Tsanas; Amaal Aldakheel; Barbara S. Connolly; Carmen Gasca-Salas; Drew S. Kern; Jennifer Jain; Elizabeth J. Slow; Achinoam Faust-Socher; Anthony E. Lang; Max A. Little; Connie Marras

doi:10.3233/JPD-181389

Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson's disease

Siddharth Arora, Naomi P. Visanji, Tiago A. Mestre, Athanasios Tsanas, Amaal Aldakheel, Barbara S. Connolly, Carmen Gasca-Salas, Drew S. Kern, Jennifer Jain, Elizabeth J. Slow, Achinoam Faust-Socher, Anthony E. Lang, Max A. Little, Connie Marras^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.

Original language	English
Pages (from-to)	503-510
Number of pages	8
Journal	Journal of Parkinson's Disease
Volume	8
Issue number	4
DOIs	https://doi.org/10.3233/JPD-181389
State	Published - 2018
Externally published	Yes

Funding

Funders	Funder number
Parkinson’s UK, Radboud UMC
University of Colorado Skin Disease Research Center
National Institutes of Health
Michael J. Fox Foundation for Parkinson's Research
Parkinson Society Canada
Parkinson's UK
Aston University
University of British Columbia

Keywords

LRRK2 mutation
Parkinson's disease
biomarker
voice

Access to Document

10.3233/JPD-181389

Cite this

Arora, S., Visanji, N. P., Mestre, T. A., Tsanas, A., Aldakheel, A., Connolly, B. S., Gasca-Salas, C., Kern, D. S., Jain, J., Slow, E. J., Faust-Socher, A., Lang, A. E., Little, M. A., & Marras, C. (2018). Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson's disease. Journal of Parkinson's Disease, 8(4), 503-510. https://doi.org/10.3233/JPD-181389

@article{a6bbd61b487944fa86e9e0ba2214a9c7,

title = "Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson's disease",

abstract = "We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.",

keywords = "LRRK2 mutation, Parkinson's disease, biomarker, voice",

author = "Siddharth Arora and Visanji, {Naomi P.} and Mestre, {Tiago A.} and Athanasios Tsanas and Amaal Aldakheel and Connolly, {Barbara S.} and Carmen Gasca-Salas and Kern, {Drew S.} and Jennifer Jain and Slow, {Elizabeth J.} and Achinoam Faust-Socher and Lang, {Anthony E.} and Little, {Max A.} and Connie Marras",

year = "2018",

doi = "10.3233/JPD-181389",

language = "אנגלית",

volume = "8",

pages = "503--510",

journal = "Journal of Parkinson's Disease",

issn = "1877-7171",

publisher = "SAGE Publications Ltd",

number = "4",

}

Arora, S, Visanji, NP, Mestre, TA, Tsanas, A, Aldakheel, A, Connolly, BS, Gasca-Salas, C, Kern, DS, Jain, J, Slow, EJ, Faust-Socher, A, Lang, AE, Little, MA & Marras, C 2018, 'Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson's disease', Journal of Parkinson's Disease, vol. 8, no. 4, pp. 503-510. https://doi.org/10.3233/JPD-181389

TY - JOUR

T1 - Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson's disease

AU - Arora, Siddharth

AU - Visanji, Naomi P.

AU - Mestre, Tiago A.

AU - Tsanas, Athanasios

AU - Aldakheel, Amaal

AU - Connolly, Barbara S.

AU - Gasca-Salas, Carmen

AU - Kern, Drew S.

AU - Jain, Jennifer

AU - Slow, Elizabeth J.

AU - Faust-Socher, Achinoam

AU - Lang, Anthony E.

AU - Little, Max A.

AU - Marras, Connie

PY - 2018

Y1 - 2018

N2 - We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.

AB - We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.

KW - LRRK2 mutation

KW - Parkinson's disease

KW - biomarker

KW - voice

UR - http://www.scopus.com/inward/record.url?scp=85055144464&partnerID=8YFLogxK

U2 - 10.3233/JPD-181389

DO - 10.3233/JPD-181389

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 30248062

AN - SCOPUS:85055144464

SN - 1877-7171

VL - 8

SP - 503

EP - 510

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

IS - 4

ER -

Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson's disease

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this